Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/26/2015 08/27/2015 08/28/2015 08/31/2015 09/01/2015 Date
11.62(c) 11.99(c) 11.93(c) 11.79(c) 12.06 Last
763 296 923 912 780 000 832 343 382 783 Volume
+4.97% +3.18% -0.50% -1.17% +2.29% Change
More quotes
Financials ($)
Sales 2015 112 M
EBIT 2015 -29,3 M
Net income 2015 -30,5 M
Debt 2015 -
Yield 2015 -
Sales 2016 153 M
EBIT 2016 -16,7 M
Net income 2016 -18,9 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 4,46x
Capi. / Sales 2016 3,26x
Capitalization 499 M
More Financials
Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.Its product portfolio includes Fanapt and Tasimelteon.The Fanapt product is a compound for the treatment of schizophrenia, the... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
08/20 VANDA PHARMACEUTICALS : to Present at the Canaccord Genuity Annual Growth Confer..
08/12 VANDA PHARMACEUTICALS : Announces Listing of Four New Fanapt® Patents in the FDA..
08/12 VANDA PHARMACEUTICALS : HETLIOZ® tasimelteon Phase III SET and RESET Trial Resul..
08/10 VANDA PHARMACEUTICALS : to Present at the Canaccord Genuity Annual Growth Confer..
08/05 VANDA PHARMACEUTICALS : HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Res..
08/03 VANDA PHARMACEUTICALS : Announces Listing of Four New Fanapt® Patents in the FDA..
07/31 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
07/29 VANDA PHARMACEUTICALS : reports 2Q loss
More news
Sector news : Bio Therapeutic Drugs
08:01a INCYTE : to Present at Upcoming Investor Conferences
08/31 GENMAB A/S : Total Number of Voting Rights and Total Share Capital
08/31 MEDICINES : shares surge on upbeat cholesterol drug study
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/21 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
07/31 PREMARKET BIOTECH DIGEST : Amgen Beats, GlaxoSmithKline Corruption Charges, VTv ..
07/30 PREMARKET BIOTECH DIGEST : Familial Hypercholesterolemia, Dynavax BLA Track, Ear..
07/29 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2015 Results - ..
07/29 Vanda Pharmaceuticals beats by $0.16, beats on revenue


Comments 
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions